- Home
- INBX vs ALDX Comparison
INBX vs ALDX Comparison
Compare INBX & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INBX
- ALDX
- Stock Information
- Founded
- INBX 2010
- ALDX 2004
- Country
- INBX United States
- ALDX United States
- Employees
- INBX N/A
- ALDX N/A
- Industry
- INBX Biotechnology: Pharmaceutical Preparations
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- INBX Health Care
- ALDX Health Care
- Exchange
- INBX Nasdaq
- ALDX Nasdaq
- Market Cap
- INBX 345.8M
- ALDX 342.3M
- IPO Year
- INBX 2020
- ALDX 2014
- Fundamental
- Price
- INBX $27.52
- ALDX $5.39
- Analyst Decision
- INBX Hold
- ALDX Strong Buy
- Analyst Count
- INBX 2
- ALDX 2
- Target Price
- INBX N/A
- ALDX $9.50
- AVG Volume (30 Days)
- INBX 113.1K
- ALDX 776.7K
- Earning Date
- INBX 11-13-2025
- ALDX 11-06-2025
- Dividend Yield
- INBX N/A
- ALDX N/A
- EPS Growth
- INBX N/A
- ALDX N/A
- EPS
- INBX N/A
- ALDX N/A
- Revenue
- INBX $1,400,000.00
- ALDX N/A
- Revenue This Year
- INBX N/A
- ALDX N/A
- Revenue Next Year
- INBX N/A
- ALDX $63.48
- P/E Ratio
- INBX N/A
- ALDX N/A
- Revenue Growth
- INBX N/A
- ALDX N/A
- 52 Week Low
- INBX $10.81
- ALDX $1.14
- 52 Week High
- INBX $30.23
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- INBX 58.56
- ALDX 45.98
- Support Level
- INBX $27.51
- ALDX $5.48
- Resistance Level
- INBX $30.23
- ALDX $5.88
- Average True Range (ATR)
- INBX 1.47
- ALDX 0.27
- MACD
- INBX -0.09
- ALDX -0.07
- Stochastic Oscillator
- INBX 54.53
- ALDX 1.87
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.